Literature DB >> 12118371

Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera.

Dongsheng Chen1, Elinor Washbrook, Naveed Sarwar, Gaynor J Bates, Paul E Pace, Vatsala Thirunuvakkarasu, Jacqueline Taylor, Richard J Epstein, Frances V Fuller-Pace, Jean-Marc Egly, R Charles Coombes, Simak Ali.   

Abstract

Estrogen receptor alpha (ERalpha) is a transcription factor that regulates expression of target genes in a ligand-dependent manner. Activation of gene expression is mediated by two transcription activation functions AF-1 and AF-2, which act in a promoter- and cell-specific manner. Whilst AF-2 activity is regulated by estrogen (E2) binding, the activity of AF-1 is additionally modulated by phosphorylation at several sites. One of these phosphorylation sites, serine 118 (S118) is of particular interest as its mutation significantly reduces ERalpha activity. Previous studies have shown that S118 can be phosphorylated by the ERK1/2 mitogen activated protein kinases (MAPK) and by the cyclin-dependent protein kinase Cdk7. In this study we use antisera that specifically recognize ERalpha phosphorylated at S118 to demonstrate that MAPK phosphorylates S118 in a ligand-independent manner, whereas Cdk7 mediates E2-induced phosphorylation of S118. E2 stimulation of S118 phosphorylation was observed within 10 min of its addition and was maximal at 10(-7) M E2. S118 phosphorylation was maximal at 30 min but then declined, such that by 180 min following E2 addition little S118 phosphorylation was evident. S118 phosphorylation was also induced by the partial estrogen antagonist 4-hydroxytamoxifen, but not by the complete antagonist ICI 182, 780. S118 phosphorylation upon addition of the MAPK inducers EGF or PMA followed the expected time courses. Finally, we show that ERalpha is phosphorylated at S118 in vivo using immunoblotting of extracts prepared from a series of ERalpha-positive breast tumours.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12118371     DOI: 10.1038/sj.onc.1205420

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  81 in total

1.  Headway in resistance to endocrine therapy in breast cancer.

Authors:  Yali Xu; Qiang Sun
Journal:  J Thorac Dis       Date:  2010-09       Impact factor: 2.895

2.  Activation of central, but not peripheral, estrogen receptors is necessary for estradiol's anorexigenic effect in ovariectomized rats.

Authors:  Heidi M Rivera; Lisa A Eckel
Journal:  Endocrinology       Date:  2010-11-10       Impact factor: 4.736

Review 3.  Estrogen and progesterone receptors: from molecular structures to clinical targets.

Authors:  Stephan Ellmann; Heinrich Sticht; Falk Thiel; Matthias W Beckmann; Reiner Strick; Pamela L Strissel
Journal:  Cell Mol Life Sci       Date:  2009-03-31       Impact factor: 9.261

Review 4.  Mechanisms of aromatase inhibitor resistance.

Authors:  Cynthia X Ma; Tomás Reinert; Izabela Chmielewska; Matthew J Ellis
Journal:  Nat Rev Cancer       Date:  2015-05       Impact factor: 60.716

5.  Activation of estrogen receptor-alpha reduces aortic smooth muscle differentiation.

Authors:  Christine R Montague; Melissa G Hunter; Mikhail A Gavrilin; Gary S Phillips; Pascal J Goldschmidt-Clermont; Clay B Marsh
Journal:  Circ Res       Date:  2006-07-27       Impact factor: 17.367

6.  Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells.

Authors:  Caroline E Ford; Elin J Ekström; Tommy Andersson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

Review 7.  Pathways to tamoxifen resistance.

Authors:  Rebecca B Riggins; Randy S Schrecengost; Michael S Guerrero; Amy H Bouton
Journal:  Cancer Lett       Date:  2007-05-01       Impact factor: 8.679

8.  Estrogen receptor alpha (ERalpha) phospho-serine-118 is highly expressed in human uterine leiomyomas compared to matched myometrium.

Authors:  Tonia L Hermon; Alicia B Moore; Linda Yu; Grace E Kissling; Frank J Castora; Darlene Dixon
Journal:  Virchows Arch       Date:  2008-10-14       Impact factor: 4.064

9.  The Phosphorylated Estrogen Receptor α (ER) Cistrome Identifies a Subset of Active Enhancers Enriched for Direct ER-DNA Binding and the Transcription Factor GRHL2.

Authors:  Kyle T Helzer; Mary Szatkowski Ozers; Mark B Meyer; Nancy A Benkusky; Natalia Solodin; Rebecca M Reese; Christopher L Warren; J Wesley Pike; Elaine T Alarid
Journal:  Mol Cell Biol       Date:  2019-01-16       Impact factor: 4.272

Review 10.  Estrogen and the female heart.

Authors:  A A Knowlton; D H Korzick
Journal:  Mol Cell Endocrinol       Date:  2014-01-22       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.